Aptorum Group Ltd
NASDAQ:APM

Watchlist Manager
Aptorum Group Ltd Logo
Aptorum Group Ltd
NASDAQ:APM
Watchlist
Price: 1.35 USD 0.75% Market Closed
Market Cap: 11m USD

ROCE
Return on Capital Employed

-14.8%
Current
-73%
Average
-26.1%
Industry
Created with Highcharts 11.4.8Jan '19Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25-100%-50%0%

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
-14.8%
=
EBIT
-2.2m
/
Capital Employed
16.7m

ROCE Across Competitors

Aptorum Group Ltd
Glance View

Market Cap
11m USD
Industry
Biotechnology

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

APM Intrinsic Value
Not Available
What is Return on Capital Employed?

ROCE, or Return on Capital Employed, is a financial ratio that measures a company’s profitability in relation to the capital it employs.

ROCE
-14.8%
=
EBIT
-2.2m
/
Capital Employed
16.7m
What is the ROCE of Aptorum Group Ltd?

Based on Aptorum Group Ltd's most recent financial statements, the company has ROCE of -14.8%.

Back to Top